New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.

Konica Minolta has agreed to acquire Ambry Genetics for up to $1 billion, the companies said on July 5, 2017, in a deal the buyer envisions as the first step in its strategy of developing a ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics defeated an appeal by Myriad Genetics to block competing DNA-based tests to determine hereditary risk for breast and ovarian cancer after a ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...